Full Text
Three-Part Pricing to Reward Pharmaceutical Innovation and Increase Access- Case of PCSK9 Inhibitors

Abstract

Authors

W Cheng JP Hlavka E Snowberg K Van Nuys DP Goldman

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×